

PRESS RELEASE

Grenchen, March 1, 2016

New products allow more flexibility in the creation of your prosthetic restoration

Thommen Medical is proud to announce the VARIOtemp and the VARIOflex, two new abutment sets for the temporary and final prosthetic restoration of single tooth or bridge restorations. VARIOtemp and VARIOflex abutments provide a perfect solution to a variety of clinical requirements by utilizing a single abutment design. To maximize restorative choice, these two abutments were developed for restorations using plastic, pressed ceramic and non-precious metal alloys. The length of the individual abutment can be shortened to adjust to the clinical situation and the material specific requirements. Additional features to the VARIOtemp and VARIOflex include greater mechanical retention, more anti-rotation protection and restorative ease for long, high suprastructures.

The new VARIOtemp and VARIOflex Abutments are available now and replace the current TEMPORARY and VARIOeco Abutments. Both abutments are only available as sets. The VARIOtemp Abutment Set will be delivered with the fabrication screw for modeling. The VARIOflex Abutment Set will come with a burn-out plastic cap and the abutment screw.

For more detailed information, please refer to the instructions for use.



VARIOtemp Abutment set

VARIOflex Abutment set

Contact

Thommen Medical AG
Neckarsulmstrasse 28
CH-2540 Grenchen
Tel. +41 61 965 90 20
Fax +41 61 965 90 21
presse@thommenmedical.com
www.thommenmedical.com



The press release is also available online: http://www.thommenmedical.com/en/company/media/press-releases.html

About Thommen Medical

Thommen Medical develops, manufactures and sells high-quality products for dental implantology, mainly the Thommen Implant System and biomaterials. Swiss precision, innovation, and functional design form the basis for all of the company's products. Thommen Medical's headquarters and and private manufacturing facility is located in Grenchen, Switzerland. Thommen Medical has subsidiaries in Switzerland, Germany, Austria, United States and Canada, and is represented by distribution partners in most other major markets of Europe, Asia and the Middle East. It is currently a privately held company, with two private investor groups and Novartis being the majority stockholders.